How would you define the success of Signant Health's eConsent solution for clinical trials?

Introduction

Defining the success of Signant Health's eConsent solution for clinical trials requires a comprehensive approach that considers multiple stakeholders and metrics. To address this product success metrics challenge effectively, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Signant Health's eConsent solution is a digital platform designed to streamline the informed consent process in clinical trials. It replaces traditional paper-based consent forms with an interactive, multimedia experience that aims to improve patient understanding and engagement.

Key stakeholders include:

1. Patients/trial participants
2. Clinical research organizations (CROs)
3. Pharmaceutical companies
4. Regulatory bodies
5. Healthcare providers

The user flow typically involves:

1. Patient receives an invitation to participate in a trial
2. Patient accesses the eConsent platform
3. Patient reviews study information through interactive content
4. Patient completes comprehension questions
5. Patient electronically signs the consent form
6. Investigator reviews and countersigns

This solution aligns with Signant Health's broader strategy of digitizing and optimizing clinical trial processes. Compared to competitors like Medidata and Oracle, Signant's eConsent solution emphasizes user-friendly design and robust data analytics capabilities.

In terms of product lifecycle, eConsent is in the growth stage, with increasing adoption across the industry but still room for significant expansion and feature enhancement.